ConductScience.org, home

Paper15728811

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Kobayashi S and 9 others. N Engl J Med, 2005. Cited by 3,373 papers, by iCite.

Cite this record

ConductScience Library. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. Papers, record 15728811. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/15728811

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
PubMed
Journal
N Engl J Med
PubMed
Year
2005
PubMed
Publication types
Case Reports, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
3,373
iCite
Relative citation ratio, by iCite
65.9
iCite
Revised in PubMed
2024-12-19
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kobayashi SSusumu
2Boggon TJTitus J
3Dayaram TTajhal
4Jänne PAPasi A
5Kocher OOlivier
6Meyerson MMatthew
7Johnson BEBruce E
8Eck MJMichael J
9Tenen DGDaniel G
10Halmos BBalázs

Source PubMed

Download CSV of authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Carcinoma, Non-Small-Cell LungMajor topic
Drug Resistance, NeoplasmMajor topic
ErbB ReceptorsMajor topic
Lung NeoplasmsMajor topic
QuinazolinesMajor topic
Aged
Biopsy
DNA, Neoplasm
Erlotinib Hydrochloride
Gefitinib
Humans
Male
Models, Structural
Molecular Structure
Neoplasm Recurrence, Local
Point Mutation
RNA, Neoplasm
Sequence Analysis, DNA
Sequence Analysis, RNA

Source PubMed

Download CSV of topics

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
1K12CA87723-01NCI NIH HHSUnited StatesK12CA877230PubMedNIH RePORTER
PA20-CA090578-01A1NCI NIH HHSUnited StatesPubMedPubMed
K12CA087723NIHNIH RePORTER
P20CA090578NIHNIH RePORTER
P50CA090578NIHNIH RePORTER

Download CSV of grants

Trials5

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT01480141A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)BackgroundClinicalTrials.gov
NCT01542437Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung CancerBackgroundClinicalTrials.gov
NCT01562028BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)BackgroundClinicalTrials.gov
NCT01880515Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW2992 (Afatinib)BackgroundClinicalTrials.gov
NCT05998993Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)BackgroundClinicalTrials.gov

Download CSV of trials

Comments and corrections3

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in15728818Chasing mutations in the epidermal growth factor in lung cancer.https://conductscience.org/library/papers/15728818PubMed
Comment in15901872EGFR mutation and response of lung cancer to gefitinib.https://conductscience.org/library/papers/15901872PubMed
Comment in16264986EGFR point mutation confers resistance to gefitinib in a patient with non-small-cell lung cancer.https://conductscience.org/library/papers/16264986PubMed

Download CSV of comments and corrections

Cited by1,832

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3,373 citations.

PMIDTitleJournalYearIn PapersSource
42917883A Structural Perspective on Non-covalent Targeting of Conserved Polar Residues in Protein Kinases.J Med Chem2026https://conductscience.org/library/papers/42917883PubMed
42902326Cancer metastasis: biological mechanisms, therapeutic bottlenecks, and emerging interventions.J Hematol Oncol2026https://conductscience.org/library/papers/42902326PubMed
42845849Base gap switches as transcriptional regulators and their applications as biosensors.Nat Sens2026https://conductscience.org/library/papers/42845849PubMed
42774563Clinical and genomic determinants of early treatment discontinuation in non-small-cell lung cancer: an analysis of the AACR Project GENIE Biopharma Collaborative NSCLC dataset.ESMO Real World Data Digit Oncol2026https://conductscience.org/library/papers/42774563PubMed
42684344Epigenetic Profiling for Early Detection and Treatment Response Monitoring in Non-Small Cell Lung Cancer: Protocol for a Prospective Translational Biomarker Study.JMIR Res Protoc2026https://conductscience.org/library/papers/42684344PubMed
42656147Towards better outcomes for epidermal growth factor receptor L858R+ lung cancer patients: mutant-selective allosteric inhibitors and the potential for double-drugging.Philos Trans R Soc Lond B Biol Sci2026https://conductscience.org/library/papers/42656147PubMed
42589611Advances in Aptamer Diagnostics Targeting Non-Small-Cell Lung Cancer: A Systematic Review.Int J Mol Sci2026https://conductscience.org/library/papers/42589611PubMed
42589609The Dual Role of Human UDP-Glucuronosyltransferase-Mediated Metabolism in Tumor Drug Resistance: Mechanisms and Prospects.Int J Mol Sci2026https://conductscience.org/library/papers/42589609PubMed
42583967Epidermal growth factor receptor as a target enzyme in cancer therapy: Structural and functional insights from crystallography.Indian J Pharmacol2026https://conductscience.org/library/papers/42583967PubMed
42572587Mycoplasma infection drives EGFR-TKI resistance through convergent transcriptomic reprogramming in non-small cell lung cancer.iScience2026https://conductscience.org/library/papers/42572587PubMed
42514920Exploiting the T790M Gatekeeper: A Theoretical Blueprint for Non-Covalent Inhibition of in cis Triple-Mutant EGFR.Pharmaceutics2026https://conductscience.org/library/papers/42514920PubMed
42512348Risk Stratification and Strategies Towards Front-Line Therapy of EGFR-Mutant NSCLC: A Narrative Review.Cancers (Basel)2026https://conductscience.org/library/papers/42512348PubMed
42463770Multiparatopic antibodies overcome tyrosine kinase inhibitor resistance by inducing lysosomal degradation of EGFR mutants.Oncogene2026https://conductscience.org/library/papers/42463770PubMed
42435178Targeting Lung Cancer Metabolism: Therapeutic Opportunities and Challenges.Adv Exp Med Biol2026https://conductscience.org/library/papers/42435178PubMed
42428346New and emerging strategies for targeting cancers: Challenges and opportunities (Review).Oncol Lett2026https://conductscience.org/library/papers/42428346PubMed
42420595Opportunities and challenges in the development of evolving EGFR inhibitors to overcome EGFR TKIs resistance.Acta Pharmacol Sin2026https://conductscience.org/library/papers/42420595PubMed
42384310Atomic degradation: chemical design strategies and immunotherapeutic mechanisms of radio-PROTACs.Ann Nucl Med2026https://conductscience.org/library/papers/42384310PubMed
42187561A Case of Primary EGFR T790M Mutation in Treatment-Naïve Advanced NSCLC: Clinical and Molecular Implications.Curr Oncol2026https://conductscience.org/library/papers/42187561PubMed
42176127Somatic mutation profiling by NGS-based liquid biopsy in advanced non-small cell lung cancer: frequency, clinical correlates, and prognostic significance.Mol Biol Rep2026https://conductscience.org/library/papers/42176127PubMed
42174661Beyond Darwin: reactive heredity, burst-drift dynamics and eco‑evolutionary control of cancer.Mol Cancer2026https://conductscience.org/library/papers/42174661PubMed

See all 1,832 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
EGFR1956PubTator's text mininghttps://conductscience.org/library/genes/1956

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/15728811

GET https://conductscience.org/api/papers/v1/15728811/cited_by?page=2